Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1999 Oct;54(10):894–899. doi: 10.1136/thx.54.10.894

Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma

R Meijer 1, H Kerstjens 1, L Arends 1, H Kauffman 1, G Koeter 1, D Postma 1
PMCID: PMC1745367  PMID: 10491451

Abstract

BACKGROUND—Guidelines state that oral and inhaled corticosteroids are the cornerstone of asthma treatment. The effect of both types of treatment can be assessed by measuring lung and systemic parameters. Treatment for two weeks with either oral prednisolone (30 mg/day), high dose fluticasone propionate (2000 µg/day, FP2000), or lower dose FP (500 µg/day, FP500), both given by a dry powder inhaler, were compared.
METHODS—One hundred and twenty patients with asthma were treated for two weeks in a double blind parallel group design. Lung function, asthma symptoms, airway hyperresponsiveness (PC20 methacholine and adenosine-5'-monophosphate), sputum eosinophil and eosinophilic cationic protein (ECP) levels were measured as lung parameters. In addition, morning serum blood cortisol, blood eosinophil, and serum ECP levels were measured as systemic parameters.
RESULTS—PC20 methacholine and adenosine-5'-monophosphate showed significantly greater improvement with FP2000 (1.99 and 4.04 doubling concentrations (DC), respectively) than prednisolone (0.90 DC, p = 0.02; 2.15 DC, p = 0.05) and marginally more than with FP500 (1.69 and 3.54 DC). Changes in sputum eosinophil and ECP concentrations showed similar trends; the decrease in ECP was significantly greater with FP2000 than with FP500. In contrast, the systemic parameters of steroid activity (cortisol, peripheral blood eosinophils, and serum ECP) decreased to a similar extent with FP2000 and prednisolone but significantly less with FP500.
CONCLUSIONS—Oral prednisolone (30 mg/day) was inferior to FP2000 in improving airway hyperresponsiveness to both methacholine and AMP, with similar trends in forced expiratory volume in one second (FEV1), sputum eosinophil and ECP concentrations. Systemic effects were similar with prednisolone and FP2000 and less with FP500.



Full Text

The Full Text of this article is available as a PDF (87.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentley A. M., Hamid Q., Robinson D. S., Schotman E., Meng Q., Assoufi B., Kay A. B., Durham S. R. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996 Feb;153(2):551–556. doi: 10.1164/ajrccm.153.2.8564096. [DOI] [PubMed] [Google Scholar]
  2. Boe J., Bakke P., Rødølen T., Skovlund E., Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society. Eur Respir J. 1994 Dec;7(12):2179–2184. doi: 10.1183/09031936.94.07122179. [DOI] [PubMed] [Google Scholar]
  3. Bosman H. G., van Uffelen R., Tamminga J. J., Paanakker L. R. Comparison of inhaled beclomethasone dipropionate 1000 micrograms twice daily and oral prednisone 10 mg once daily in asthmatic patients. Thorax. 1994 Jan;49(1):37–40. doi: 10.1136/thx.49.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chervinsky P., van As A., Bronsky E. A., Dockhorn R., Noonan M., LaForce C., Pleskow W. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol. 1994 Oct;94(4):676–683. doi: 10.1016/0091-6749(94)90174-0. [DOI] [PubMed] [Google Scholar]
  5. Claman D. M., Boushey H. A., Liu J., Wong H., Fahy J. V. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol. 1994 Nov;94(5):861–869. doi: 10.1016/0091-6749(94)90154-6. [DOI] [PubMed] [Google Scholar]
  6. Clark D. J., Lipworth B. J. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997 Jan;52(1):55–58. doi: 10.1136/thx.52.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dahl R., Lundback B., Malo J. L., Mazza J. A., Nieminen M. M., Saarelainen P., Barnacle H. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest. 1993 Nov;104(5):1352–1358. doi: 10.1378/chest.104.5.1352. [DOI] [PubMed] [Google Scholar]
  8. Djukanović R., Homeyard S., Gratziou C., Madden J., Walls A., Montefort S., Peroni D., Polosa R., Holgate S., Howarth P. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med. 1997 Mar;155(3):826–832. doi: 10.1164/ajrccm.155.3.9117012. [DOI] [PubMed] [Google Scholar]
  9. Esmailpour N., Högger P., Rabe K. F., Heitmann U., Nakashima M., Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997 Jul;10(7):1496–1499. doi: 10.1183/09031936.97.10071496. [DOI] [PubMed] [Google Scholar]
  10. Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fuller R., Johnson M., Bye A. Fluticasone propionate--an update on preclinical and clinical experience. Respir Med. 1995 Sep;89 (Suppl A):3–18. doi: 10.1016/0954-6111(95)90259-7. [DOI] [PubMed] [Google Scholar]
  12. Greos L. S., Vichyanond P., Bloedow D. C., Irvin C. G., Larsen G. L., Szefler S. J., Hill M. R. Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):586–592. doi: 10.1164/ajrccm/144.3_Pt_1.586. [DOI] [PubMed] [Google Scholar]
  13. Högger P., Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597–602. doi: 10.1016/0039-128x(94)90054-x. [DOI] [PubMed] [Google Scholar]
  14. Inman M. D., Denburg J. A., Ellis R., Dahlbäck M., O'Byrne P. M. The effect of treatment with budesonide or PGE2 in vitro on allergen-induced increases in canine bone marrow progenitors. Am J Respir Cell Mol Biol. 1997 Nov;17(5):634–641. doi: 10.1165/ajrcmb.17.5.2746. [DOI] [PubMed] [Google Scholar]
  15. Jenkins C. R., Woolcock A. J. Effect of prednisone and beclomethasone dipropionate on airway responsiveness in asthma: a comparative study. Thorax. 1988 May;43(5):378–384. doi: 10.1136/thx.43.5.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J. 1990 Nov;3(10):1122–1127. [PubMed] [Google Scholar]
  17. Kamada A. K., Szefler S. J., Martin R. J., Boushey H. A., Chinchilli V. M., Drazen J. M., Fish J. E., Israel E., Lazarus S. C., Lemanske R. F. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1739–1748. doi: 10.1164/ajrccm.153.6.8665030. [DOI] [PubMed] [Google Scholar]
  18. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  19. Kraft M., Djukanovic R., Wilson S., Holgate S. T., Martin R. J. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med. 1996 Nov;154(5):1505–1510. doi: 10.1164/ajrccm.154.5.8912772. [DOI] [PubMed] [Google Scholar]
  20. Lawrence M., Wolfe J., Webb D. R., Chervinsky P., Kellerman D., Schaumberg J. P., Shah T. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):744–751. doi: 10.1164/ajrccm.156.3.9608058. [DOI] [PubMed] [Google Scholar]
  21. Levy M. L., Stevenson C., Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax. 1996 Nov;51(11):1087–1092. doi: 10.1136/thx.51.11.1087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McEvoy C. E., Niewoehner D. E. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest. 1997 Mar;111(3):732–743. doi: 10.1378/chest.111.3.732. [DOI] [PubMed] [Google Scholar]
  23. Meagher L. C., Cousin J. M., Seckl J. R., Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996 Jun 1;156(11):4422–4428. [PubMed] [Google Scholar]
  24. Meijer R. J., Kerstjens H. A., Postma D. S. Comparison of guidelines and self-management plans in asthma. Eur Respir J. 1997 May;10(5):1163–1172. doi: 10.1183/09031936.97.10051163. [DOI] [PubMed] [Google Scholar]
  25. Oosterhoff Y., Koëter G. H., De Monchy J. G., Postma D. S. Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects. Am Rev Respir Dis. 1993 Mar;147(3):512–517. doi: 10.1164/ajrccm/147.3.512. [DOI] [PubMed] [Google Scholar]
  26. Pauwels R., Joos G., Van der Straeten M. Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. Clin Allergy. 1988 Jul;18(4):317–321. doi: 10.1111/j.1365-2222.1988.tb02878.x. [DOI] [PubMed] [Google Scholar]
  27. Pearlman D. S., Noonan M. J., Tashkin D. P., Goldstein M. F., Hamedani A. G., Kellerman D. J., Schaberg A. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol. 1997 Apr;78(4):356–362. doi: 10.1016/S1081-1206(10)63196-1. [DOI] [PubMed] [Google Scholar]
  28. Robinson D. S., Assoufi B., Durham S. R., Kay A. B. Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in asthma. Effect of prednisolone treatment. Clin Exp Allergy. 1995 Nov;25(11):1118–1127. doi: 10.1111/j.1365-2222.1995.tb03259.x. [DOI] [PubMed] [Google Scholar]
  29. Smith R. Corticosteroids and osteoporosis. Thorax. 1990 Aug;45(8):573–578. doi: 10.1136/thx.45.8.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sterk P. J., Fabbri L. M., Quanjer P. H., Cockcroft D. W., O'Byrne P. M., Anderson S. D., Juniper E. F., Malo J. L. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:53–83. [PubMed] [Google Scholar]
  31. Tan K. S., Grove A., Cargill R. I., McFarlane L. C., Lipworth B. J. Effects of inhaled fluticasone propionate and oral prednisolone on lymphocyte beta 2-adrenoceptor function in asthmatic patients. Chest. 1996 Feb;109(2):343–347. doi: 10.1378/chest.109.2.343. [DOI] [PubMed] [Google Scholar]
  32. Weersink E. J., Douma R. R., Postma D. S., Koëter G. H. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med. 1997 Apr;155(4):1241–1246. doi: 10.1164/ajrccm.155.4.9105061. [DOI] [PubMed] [Google Scholar]
  33. Woolley M. J., Denburg J. A., Ellis R., Dahlback M., O'Byrne P. M. Allergen-induced changes in bone marrow progenitors and airway responsiveness in dogs and the effect of inhaled budesonide on these parameters. Am J Respir Cell Mol Biol. 1994 Nov;11(5):600–606. doi: 10.1165/ajrcmb.11.5.7946389. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES